Enzalutamide Accordpharma

( ARTG ) CIP ENZALUTAMIDE is indicated for:, the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence at high-risk for metastasis (high-risk BCR)., the treatment of patients with metast​​​‍​​‍​​​​‍​​‍‍atic hormone-sensitive prostate cancer., the treatment of patients with non-metastatic castration-resistant prostate cancer (see PROSPER, section 5.1 - PHARMACODYNAMIC PROPERTIES - Clinical trials)., the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated., the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.